FDA Tightens Accelerated Approval Pathway, Rejects Regenxbio and Disc Medicine
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy RGNX?
The Food and Drug Administration review process for accelerated approvals was meant to drugs for rare diseases to pass the approval process, clearing the drugs based on early biological signs instead of waiting years for definitive proof of real-world outcomes, David Wainer of The Wall Street Journal. Now, however, the accelerated approval pathway isn't closed but has become much narrower and harder to predict. Recently, the FDA issued a string of rejections, including Regenxbio's (RGNX) gene therapy for Hunter Syndrome and Disc Medicine's (IRON) treatment for a blood disorder. In some cases, the agency reversed its own guidelines provided to the companies. In 2025, the FDA greenlighted only nine accelerated approvals, down from 20 in 2024. Other companies in the space include: uniQure (QURE), Moderna (MRNA), Replimune (REPL), and Capricor (CAPR).
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RGNX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RGNX
Wall Street analysts forecast RGNX stock price to rise
7 Analyst Rating
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 8.690
Low
19.00
Averages
29.71
High
45.00
Current: 8.690
Low
19.00
Averages
29.71
High
45.00
About RGNX
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Regenxbio to Announce Q4 Earnings on March 5
- Earnings Announcement: Regenxbio is set to announce its Q4 2023 earnings on March 5 before market open, with consensus EPS estimated at -$0.84 and revenue at $45.48 million, which will significantly impact the company's financial outlook.
- Earnings Estimate Fluctuations: Over the past three months, EPS estimates have seen one upward revision and two downward adjustments, while revenue estimates have also experienced one upward and two downward revisions, indicating a cautious market sentiment regarding Regenxbio's future performance.
- FDA Decision Impact: Regenxbio's stock has recently dropped due to setbacks with the FDA regarding the RGX-121 gene therapy, which may negatively affect market sentiment ahead of the earnings report, increasing uncertainty among investors.
- Patent Dispute Victory: Regenxbio achieved a legal victory in its patent dispute with Sarepta, which could support the company's future product development and market competitiveness, although challenges from the FDA remain a concern.
See More
REGENXBIO Presents RGX-202 Gene Therapy Updates at MDA Conference
- Clinical Data Presentation: REGENXBIO will showcase clinical data on RGX-202 at the 2026 Muscular Dystrophy Association Conference, including preclinical and Phase I/II safety, biomarker, and functional data, which is expected to bolster investor confidence in the company's R&D capabilities.
- Key Presentation Schedule: Clinical Professor Carolina Tesi Rocha will present oral data on RGX-202 on March 11, 2026, at 11:45 AM, highlighting its potential in treating Duchenne muscular dystrophy, which may attract more attention and collaboration opportunities.
- Poster Presentation Insights: Dr. Steven Foltz from REGENXBIO will present research on microdystrophin's protective effects against pharmacologically induced cardiac damage in mice, further validating RGX-202's therapeutic mechanism and potentially advancing subsequent clinical studies.
- Symposium Details: The company will host a symposium titled “Advancing Duchenne Gene Therapy Trials in a New Era” on March 9, 2026, featuring industry experts discussing optimized trial design and interpretation, aimed at enhancing the understanding and application of gene therapies in the field.
See More
REGENXBIO Investors Urged to Discuss Legal Rights Amid Significant Losses
- Legal Investigation: Faruqi & Faruqi LLP is investigating potential claims against REGENXBIO due to possible false statements made during securities transactions from February 9, 2022, to January 27, 2026, which may have harmed investors' interests.
- Clinical Trial Hold: On January 28, 2026, REGENXBIO announced that the FDA placed a clinical hold on its gene therapies RGX-111 and RGX-121 after a participant developed a tumor, causing the stock price to drop by 17.9% to $11.01 per share, significantly impacting market confidence.
- Class Action Deadline: Investors must apply by April 14, 2026, to serve as lead plaintiffs in the class action lawsuit to represent other affected investors, ensuring their rights are protected in the legal process.
- Information Solicitation: Faruqi & Faruqi LLP is urging anyone with knowledge of REGENXBIO's conduct, including former employees and shareholders, to provide information to support the ongoing legal investigation, enhancing the case's effectiveness.
See More
Notice of Class Action Lawsuit Against REGENXBIO Securities
- Class Action Deadline: Rosen Law Firm reminds investors who purchased REGENXBIO (NASDAQ:RGNX) securities between February 9, 2022, and January 27, 2026, that they must apply to be lead plaintiff by April 14, 2026, to participate in the class action and seek compensation.
- No Upfront Fees: Investors joining the class action will incur no out-of-pocket fees or costs, as the law firm operates on a contingency fee basis, thereby reducing the financial burden on investors.
- Case Background: The lawsuit alleges that defendants provided false and misleading information regarding REGENXBIO's RGX-111 gene therapy development, leading to investor losses when the true facts emerged, negatively impacting the company's reputation and stock price.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its extensive experience and success in handling such cases, prompting investors to carefully select qualified legal counsel.
See More
REGENXBIO Faces Class Action Lawsuit
- Class Action Initiated: Robbins LLP reminds investors of a class action filed on behalf of shareholders who purchased REGENXBIO (NASDAQ:RGNX) securities between February 9, 2022, and January 27, 2026, highlighting serious concerns regarding the company's transparency and investor communication.
- Drug Candidate Issues: The lawsuit alleges that REGENXBIO misled investors about the safety of its clinical-stage drug RGX-111, which was touted as receiving FDA Fast Track designation and reporting positive clinical results, while serious safety concerns were concealed from the public.
- FDA Clinical Hold: On January 28, 2026, the FDA placed a clinical hold on RGX-111 and RGX-121 due to a reported case of CNS tumor in a trial participant, causing REGENXBIO's stock to plummet 17.8% in one day, from $13.41 to $11.01 per share, reflecting a significant loss of investor confidence.
- Shareholder Action Guidance: Shareholders can submit their papers to become lead plaintiffs in the class action by April 14, 2026, indicating a need for improved corporate governance to protect investor rights, as participation in the lawsuit is not required for potential recovery.
See More
REGENXBIO to Participate in Multiple Investor Conferences
- Investor Conference Schedule: REGENXBIO will participate in the Leerink Partners and Barclays Global Healthcare Conferences on March 9 and 10 in Miami, showcasing its latest advancements in gene therapy, which is expected to attract investor interest and enhance the company's visibility.
- Virtual Conference Participation: The company will also attend the RBC Inaugural Virtual Ophthalmology Conference on March 24, further expanding its influence in the ophthalmology field by presenting its treatment options for wet AMD and diabetic retinopathy.
- Pioneering Gene Therapy: Since its founding in 2009, REGENXBIO has made significant strides in AAV gene therapy, advancing a late-stage pipeline for rare and retinal diseases, demonstrating its leadership position in the biotechnology sector.
- Patient Treatment Potential: The gene therapies developed by the company have provided treatment opportunities for thousands of patients, particularly with ZOLGENSMA® in collaboration with Novartis, indicating the potential of its treatment options to transform healthcare delivery for millions.
See More
Regenxbio to Announce Q4 Earnings on March 5
- Earnings Announcement: Regenxbio is set to announce its Q4 2023 earnings on March 5 before market open, with consensus EPS estimated at -$0.84 and revenue at $45.48 million, which will significantly impact the company's financial outlook.
- Earnings Estimate Fluctuations: Over the past three months, EPS estimates have seen one upward revision and two downward adjustments, while revenue estimates have also experienced one upward and two downward revisions, indicating a cautious market sentiment regarding Regenxbio's future performance.
- FDA Decision Impact: Regenxbio's stock has recently dropped due to setbacks with the FDA regarding the RGX-121 gene therapy, which may negatively affect market sentiment ahead of the earnings report, increasing uncertainty among investors.
- Patent Dispute Victory: Regenxbio achieved a legal victory in its patent dispute with Sarepta, which could support the company's future product development and market competitiveness, although challenges from the FDA remain a concern.
See More
REGENXBIO Presents RGX-202 Gene Therapy Updates at MDA Conference
- Clinical Data Presentation: REGENXBIO will showcase clinical data on RGX-202 at the 2026 Muscular Dystrophy Association Conference, including preclinical and Phase I/II safety, biomarker, and functional data, which is expected to bolster investor confidence in the company's R&D capabilities.
- Key Presentation Schedule: Clinical Professor Carolina Tesi Rocha will present oral data on RGX-202 on March 11, 2026, at 11:45 AM, highlighting its potential in treating Duchenne muscular dystrophy, which may attract more attention and collaboration opportunities.
- Poster Presentation Insights: Dr. Steven Foltz from REGENXBIO will present research on microdystrophin's protective effects against pharmacologically induced cardiac damage in mice, further validating RGX-202's therapeutic mechanism and potentially advancing subsequent clinical studies.
- Symposium Details: The company will host a symposium titled “Advancing Duchenne Gene Therapy Trials in a New Era” on March 9, 2026, featuring industry experts discussing optimized trial design and interpretation, aimed at enhancing the understanding and application of gene therapies in the field.
See More
REGENXBIO Investors Urged to Discuss Legal Rights Amid Significant Losses
- Legal Investigation: Faruqi & Faruqi LLP is investigating potential claims against REGENXBIO due to possible false statements made during securities transactions from February 9, 2022, to January 27, 2026, which may have harmed investors' interests.
- Clinical Trial Hold: On January 28, 2026, REGENXBIO announced that the FDA placed a clinical hold on its gene therapies RGX-111 and RGX-121 after a participant developed a tumor, causing the stock price to drop by 17.9% to $11.01 per share, significantly impacting market confidence.
- Class Action Deadline: Investors must apply by April 14, 2026, to serve as lead plaintiffs in the class action lawsuit to represent other affected investors, ensuring their rights are protected in the legal process.
- Information Solicitation: Faruqi & Faruqi LLP is urging anyone with knowledge of REGENXBIO's conduct, including former employees and shareholders, to provide information to support the ongoing legal investigation, enhancing the case's effectiveness.
See More
Notice of Class Action Lawsuit Against REGENXBIO Securities
- Class Action Deadline: Rosen Law Firm reminds investors who purchased REGENXBIO (NASDAQ:RGNX) securities between February 9, 2022, and January 27, 2026, that they must apply to be lead plaintiff by April 14, 2026, to participate in the class action and seek compensation.
- No Upfront Fees: Investors joining the class action will incur no out-of-pocket fees or costs, as the law firm operates on a contingency fee basis, thereby reducing the financial burden on investors.
- Case Background: The lawsuit alleges that defendants provided false and misleading information regarding REGENXBIO's RGX-111 gene therapy development, leading to investor losses when the true facts emerged, negatively impacting the company's reputation and stock price.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its extensive experience and success in handling such cases, prompting investors to carefully select qualified legal counsel.
See More
REGENXBIO Faces Class Action Lawsuit
- Class Action Initiated: Robbins LLP reminds investors of a class action filed on behalf of shareholders who purchased REGENXBIO (NASDAQ:RGNX) securities between February 9, 2022, and January 27, 2026, highlighting serious concerns regarding the company's transparency and investor communication.
- Drug Candidate Issues: The lawsuit alleges that REGENXBIO misled investors about the safety of its clinical-stage drug RGX-111, which was touted as receiving FDA Fast Track designation and reporting positive clinical results, while serious safety concerns were concealed from the public.
- FDA Clinical Hold: On January 28, 2026, the FDA placed a clinical hold on RGX-111 and RGX-121 due to a reported case of CNS tumor in a trial participant, causing REGENXBIO's stock to plummet 17.8% in one day, from $13.41 to $11.01 per share, reflecting a significant loss of investor confidence.
- Shareholder Action Guidance: Shareholders can submit their papers to become lead plaintiffs in the class action by April 14, 2026, indicating a need for improved corporate governance to protect investor rights, as participation in the lawsuit is not required for potential recovery.
See More
REGENXBIO to Participate in Multiple Investor Conferences
- Investor Conference Schedule: REGENXBIO will participate in the Leerink Partners and Barclays Global Healthcare Conferences on March 9 and 10 in Miami, showcasing its latest advancements in gene therapy, which is expected to attract investor interest and enhance the company's visibility.
- Virtual Conference Participation: The company will also attend the RBC Inaugural Virtual Ophthalmology Conference on March 24, further expanding its influence in the ophthalmology field by presenting its treatment options for wet AMD and diabetic retinopathy.
- Pioneering Gene Therapy: Since its founding in 2009, REGENXBIO has made significant strides in AAV gene therapy, advancing a late-stage pipeline for rare and retinal diseases, demonstrating its leadership position in the biotechnology sector.
- Patient Treatment Potential: The gene therapies developed by the company have provided treatment opportunities for thousands of patients, particularly with ZOLGENSMA® in collaboration with Novartis, indicating the potential of its treatment options to transform healthcare delivery for millions.
See More
